Wednesday, November 14

Anal Cancer (Real Life Story)


(How Are They Connected)

Rising rates of anal cancer among men in the USA have been heavily influenced by the HIV epidemic since the 1980s, a study shows.
However, the authors found that while rates of anal cancer are higher in women than men, and have also increased during the same period, HIV infection has not significantly contributed to this.
Meredith Shiels (National Cancer Institute, Rockville, Maryland) and colleagues used data collected between 1980 and 2005 from the HIV/AIDS Cancer Match (HACM) Study, which incorporates 17 HIV/AIDS and cancer registries. During this time there were 20,533 anal cancer cases, of which 1665 (8.1%) occurred in HIV-infected patients.
Between 1980 and 1984 and 2001 and 2005, the incidence of anal cancer rose from 0.44 to 0.93 cases per 100,000 men and the proportion of anal cancers in HIV-positive men rose from 1.1% to 28.4%. Overall, 83.5% of HIV-infected anal cancer cases were in men who have sex with men.

Rates of anal cancer also increased in women. The authors estimated that between 1980 and 1984 and 2001 and 2005 the incidence of anal cancer rose from 0.68 to 1.29 per 100,000 years, and the proportion of anal cancer among HIV-positive women rose from 0% to 1.2%.
Shiels and colleagues found that while HIV-infected anal cancer cases strongly influenced the overall trend in incidence in men, exclusion of HIV-related cases had no effect on the increase in incidence rate in women.

While anal cancer is rare in the USA, it is the fourth most common cancer among HIV-infected individuals. The authors say that the association is likely to be related to anal human papillomavirus (HPV) infection, which is transmitted during anal sex. HIV-related immunosuppression may also impair the immune response to HPV infection, making HIV-infected individuals more susceptible to anal cancer.
They say that their findings could influence potential public health strategies such as HPV vaccination or Papanicolaou testing.

"Measures that would effectively prevent anal cancer in HIV-infected males could markedly reduce anal cancer rates at the population level," they write in the Journal of the National Cancer Institute. "In contrast, very few females with anal cancer were HIV-infected, and more research is needed to understand causes of rising anal cancer incidence in females."

The presence of palpable, clinically involved inguinal lymph nodes (PCIINs) and male gender are both independent risk factors for poor prognosis in anal cancer, confirm the results of a UK analysis.
The researchers analyzed data from 292 patients in the Anal Cancer Trial (ACT) I trial who received chemoradiation between 1987 and 1994. From this, they generated prognostic scores for locoregional failure at 2 years, anal cancer death at 5 years, and overall survival at 5 years.
Regression analysis showed that male gender and PCIINs were independent risk factors for all three endpoints.

In comparison with women, the risk for locoregional failure was 60% greater (36 vs 26%), for anal cancer death was 80% greater (39 vs 25%), and for any death was 56% greater for men (82 vs 57%). Meanwhile, the presence of PCIINs increased the risk for locoregional failure by 87% (40 vs 28%), and for anal cancer death by 83% (45 vs 27%), and led to significantly worse overall survival compared with patients with inpalpable nodes.

After adjusting for gender and lymph node status, the authors also found that lower hemoglobin level increased the risk for anal cancer death, while increased baseline white blood cell count reduced overall survival.

"The use of hemoglobin as a risk-stratification factor may be useful in future trials and may provide a method with which to identify patients who might benefit from future methods of hypoxic modification of radiotherapy," Robert Glynne-Jones (Mount Vernon Center for Cancer Treatment, Northwood, UK) and colleagues write in Cancer.

They add that pretreatment white blood cell count may be prognostic due to the role of inflammation in cancer progression.

Effects of Chemotherapy




Chemotherapy is the treatment of cancer with one or more cytotoxic antineoplastic drugs ("chemotherapeutic agents") as part of a standardized regimen. Chemotherapy may be given with acurative intent or it may aim to prolong life or to palliate symptoms. It is often used in conjunction with other cancer treatments, such as radiation therapy or surgery.
Some newer anticancer drugs (for example, various monoclonal antibodies) are not indiscriminately cytotoxic, but rather target proteins that are abnormally expressed in cancer cells and that are essential for their growth. Such treatments are often referred to as targeted therapy (as distinct from classic chemotherapy) and are often used alongside traditional chemotherapeutic agents in antineoplastic treatment regimens.

Sunday, October 28

Comprehensive Treatment for Breast Cancer

Do You Know Someone Who Has It?

Watch this Doctor and their New Methods in treating and managing Breast Cancer patients in their Hospital.

For those who wanted to know more about their methods.

Free Breast Cancer Discussion and Q & A with Dr. Steven Schonholz

CHD's Cancer House of Hope will host a free breast cancer discussion and Q & A with Dr. Steven Schonholz, breast surgeon and director of Noble Hospital's Comprehensive Breast Program. Dr. Schonholz will address general topics specific to a breast cancer diagnosis and take questions from the audience.
The discussion will take place at 7:15pm on Thursday, October 25, at CHD's Cancer House of Hope, 86 Court Street, Westfield. To register, please call 413-562-0110.

Dr. Steven Schonholz
Mercy Medical Center
271 Carew St
Springfield, MA 01104

Dr. Steven Schonholz specializes in general surgery in Springfield, Massachusetts. Details of Dr. Schonholz's 30 years experience as a MD, his hospital affiliation and education at Mount Sinai School of Medicine.

Friday, October 12


Latest Breast Cancer Detector for Women

Devised and Designed by Dr. Elias Siores of the UK's University of Bolton in 2007, the bra has been tested for sensitivity and accuracy in three clinical trials involving 650 subjects—and now nearly on completion toward being a marketable product. The company, First Warning Systems, a final clinical trial is being planned. But so far, so good: studies have shown it can indicate cancer up to six years before a tumor can be detected by imaging,


The bra works via its microwave antennae system woven into the fabric. Using the science of thermography, it can detect slight temperature changes as the result of increased blood flow, which could signal the development of breast cancer tumors. Users can track the signals on a computer or smartphone, and elevation in temperatures will set off a warning for users to call their doctor. "And while getting a weekly mammogram to catch breast cancer in its earliest stages is impractical, wearing a smart sports bra that's just as effective at early detection isn't," writes Gizmodo on Wednesday, adding that this bra has potential to "revolutionize screenings."

Ttraditional screenings are not as effective for women under 40 due to their denser breast tissue, this could prove a viable option. However, since women will need to wear the bra regularly to detect changes, it might not be that practical for some women. Assuming the final clinical trial yields positive results, the bra could hit the market next year in Europe and potentially in the US in 2014, pending approval from the Food and Drug Administration.
So who will be the first to test and use this new generation bra!

Breast Cancer And Hormone Therapy

Is Hormone Therapy Safe for Breast Cancer?

Many postmenopausal women are looking for alternatives to hormone therapy, especially in light of the recent Women's Health Initiative research findings concerning the risks of combined estrogen and progestin therapy. Of particular interest are phytoestrogens, which have been gaining popularity due to their "natural" status, alleged health claims, and availability in a wide range of foods and supplements.


Phytoestrogens are naturally occurring plant compounds that have some similarities to estradiol, the most potent naturally occurring estrogen. However, phytoestrogens tend to have weaker effects than most estrogens, are not stored in the body, and can be easily broken down and eliminated.

Observational studies have found a lower prevalence of breast cancer, heart disease and hip fracture rates among people living in places like Southeast Asia, where diets are typically high in phytoestrogens. In North America, knowledge of these reported health effects has stimulated great interest in the health benefits of phytoestrogens. According to the Food and Drug Administration, the sale of soy foods, a major source of phytoestrogens, has increased dramatically in the past decade.

Sources of Phytoestrogens

Phytoestrogens consist of more than 20 compounds and can be found in more than 300 plants, such as herbs, grains and fruits. The three main classes of dietary phytoestrogens are isoflavones, lignans and coumestans:

1. Isoflavones (genistein, daidzein, glycitein and equol) are primarily found in soy beans and soy products, chickpeas and other legumes.

2. Lignans (enterolactone and enterodiol) are found in seeds (primarily flaxseed), cereal bran, legumes, and alcohol (beer and bourbon).

3. Coumestans (coumestrol) can be found in alfalfa and clover. Most food sources containing these compounds typically include more than one class of phytoestrogens.

The Skeletal Effects of Phytoestrogens

Much of the evidence concerning the potential role of phytoestrogens in bone health is based on animal studies. In fact, soybean protein, soy isoflavones, genistein, daidzein and coumestrol have all been shown to have a protective effect on bone in animals who had their ovaries surgically removed.

In humans, however, the evidence is conflicting. Compared to Caucasian populations, documented hip fracture rates are lower in countries such as Hong Kong, China and Japan where dietary phytoestrogen intakes are high. Yet reports suggest that Japanese women have a greater risk of sustaining a vertebral fracture than Caucasian women.

The Risks and Benefits

Some studies suggest that, unlike estrogen, phytoestrogens do not appear to target breast or uterine tissue. This suggests that they may act more like SERMS (selective estrogen receptor modulators such as raloxifene and tamoxifen) than actual estrogens. However, in other studies high isoflavone levels have been linked to an increased risk of breast cancer.

Clearly, additional research is needed to further evaluate the effects of phytoestrogens before judgments regarding their safety and usefulness can be made.

Key Points

Based on information available at this time, it is reasonable to make the following conclusions concerning phytoestrogens and bone health in postmenopausal women:

1. Moderate amounts of foods containing phytoestrogens can be safely included in the diet but do not expect it to help build bone. Keep to the basic rule - eat the least processed forms.

2. Due to a lack of evidence and concerns about safety, supplementation with synthetic isoflavones (ipriflavone) is in question.

3. Postmenopausal women are encouraged to view evidence concerning phytoestrogens and bone health as conflicting and incomplete. For women who are estrogen dominant increasing their phytoestrogen intake may not improve their bone position.

Several studies have explored the effects of soy isoflavones on bone health, but results have been mixed, ranging from a modest impact to no effect. Most of these studies have serious limitations, including their short duration and small sample size, making it difficult to fully evaluate the impact of these compounds on bone health.

Tomatillo: A Cure for Cancer?

Researchers study shows Tomatillo fights Cancer!

For decades the native prairie plant with tomato-like vines, and marbled-sized fruit covered in thin husks, has sprawled across the Kansas prairie in relative obscurity.
But scientists from around the world are now noticing the wild tomatillo, and wondering if it might provide a major medicinal breakthrough.

"We've found compounds from the wild tomatillo that have strong anti-cancer properties against breast cancer, skin cancer, thyroid cancer and brain cancer in our early studies," said Mark Cohen, cancer physician and research scientist who has been working with the plant for more than two years.
"It's very exciting that (wild tomatillo compounds) do have a strong potency effect against cancer and do not have significant toxicity against other cells so far in our evaluations," said Cohen, who is directing laboratory testing on the wild tomatillo compounds furnished by Timmermann.

Initially Cohen did so at the KU School of Medicine. He took the chores with him to a new job at the University of Michigan.

"We've found 15 new molecules in the plant previously not known to science," said Barbara TimmermannUniversity of Kansas medicinal chemistry chair. "Nobody knew they existed and several of them are so active against cancer."
And it's not like this is some super-delicate plant from some far away corner of the Amazon.
Wild tomatillos, Physalis longifolia, are a tough, prolific prairie plant currently thriving over much of the central United States.
(They're related to a domestic variety of tomatillo, but scientists don't know if it has similar characteristics.)

The Native Medicinal Plant Research Program began in 2010 as a joint venture using the strengths of the Kansas Biological Survey, the KU School of Pharmacy and the KU School of Medicine.
Timmermann and Kelly Kindscher, a biological survey senior scientist, have long seen the Kansas prairies as a potential pharmacy waiting to be explored.

"Everybody has been going to the rain forest and other exotic places for research," said Timmermann, who has about 30 years of experience researching medicinal plants, "but we knew the Midwest had so many plants nobody had ever really looked at."
Kindscher, a noted expert on America's prairies, had also learned that for centuries native tribes were utilizing a number of plants for medicinal purposes before the state was settled.

While Kindscher and crew eventually provided about 200 different species of prairie plants for testing, wild tomatillos quickly gained the most attention because of the findings in Timmermann's lab.As well as testing how the wild tomatillo compounds perform against cancer, the plants were also tested to see how they react to other kinds of human cells.

It would be possible, Cohen said, for a compound to be very aggressive against cancer but too toxic to healthy human cells to become a viable treatment.

Kindscher said some of the highest levels of cancer-fighting compounds are found in the plant's fruit. "The fruit is edible, and actually tastes very good," he said, "especially when it's ripe."
Acquiring enough of that fruit shouldn't be a problem in the future.

Wild tomatillos are so common Kindscher referred to them as "a common field weed" that grows on native prairies, pastures and farmlands, roughly from New Mexico to Montana and as far east as Ohio. "It's probably one of the few (prairie) plants that are doing about as well as ever," he said. "It's common because it can grow in a lot of areas. Unlike a lot of prairie plants it does well on disturbed soils." He said it grows well along roadsides or where the soil has been scarred by livestock. It's common in farm fields, too. Kindscher is certain it could be grown commercially, too. The perennial plant has proven to be hardy to temperature and rainfall extremes.

Heartland is a Manhattan-based bio-technology company backing plant-based research. In the spring, nearing the end of the program's second year, Timmermann was told funding would stop immediately.

But one thing this miracle plant cannot do, is pay for its own research. All three scientists said funding is now their greatest worry.

Thursday, September 6


Therapeutic Draining 

Watch and learn how you can do draining massage. this is beneficial in caring your breasts. 
Prevention is better than cure.


Saturday, July 21

CERVICAL CANCER  Destroyer of Women Cervix
(See Video below)
Cervical cancer is an uncommon type of cancer that develops in a woman’s cervix. The Cervical cancer is an uncommon type of cancer that develops in a woman’s cervix. The cervix is the entrance to the womb from the vagina.
Cervical cancer often has no symptoms in its early stages. If you have symptoms, the most common is unusual vaginal bleeding, which can occur after sex, in between periods or after the menopause.cervix is the entrance to the womb from the vagina.
Cervical cancer often has no symptoms in its early stages. If you have symptoms, the most common is unusual vaginal bleeding, which can occur after sex, in between periods or after the menopause.

Most cervical cancer is caused by a virus called human papillomavirus, or HPV. You can get HPV by having sexual contact with someone who has it. There are many types of the HPV virus. Not all types of HPV cause cervical cancer. Some of them cause genital warts, but other types may not cause any symptoms.

You can have HPV for years and not know it. It stays in your body and can lead to cervical cancer years after you were infected. This is why it is important for you to have regular Pap tests. A Pap test can find changes in cervical cells before they turn into cancer.

  • Causes and risk factors for cervical cancer have been identified and include human papillomavirus (HPV) infection, having many sexual partners,smoking, taking birth control pills, and engaging in early sexual contact.
  • HPV infection may cause cervical dysplasia, or abnormal growth of cervical cells.
  • Regular pelvic exams and Pap testing can detect precancerous changes in the cervix.
  • Precancerous changes in the cervix may be treated with cryosurgery, cauterization, or laser surgery.
  • The most common symptoms and signs of cervical cancer are abnormal bleeding and pelvic pain.
  • Cervical cancer can be diagnosed using a Pap smear or other procedures that sample the cervix tissue.
  • Chest X-raysCT scanMRI, and aPET scan may be used to determine the stage of cervical cancer.
  • Cancer of the cervix requires different treatment than cancer that begins in other parts of the uterus.
  • Treatment options for cervical cancer include radiation therapy, surgery, and chemotherapy.
  • Two vaccines, Gardasil and Cervarix, are available to prevent HPV infection.
  • The prognosis of cervical cancer depends upon the stage and type of cervical cancer and the tumorsize.
Human papillomavirus(HPV) infection of the cervix can lead to cervical cancer. A vaccine designed to prevent cervical cancer and other diseases caused by infection with HPVs was approved for use in the U.S. in June 2006. This is the first vaccine to be developed against a known risk factor for the development of a cancer.

While some HPV types infect the skin and cause benign wartsand other lesions, about 40 types of HPVs can infect the genital tract. Genital HPV infection is very common in the general population; estimates suggest that up to 50% of all sexually active people will be infected at some point in their lives. In the majority of cases, the infection does not cause any symptoms, but in somewomen, HPV infection can progress to cause precancerous and cancerous lesions of the uterine cervix. HPVs that infect the genital area are also associated with other less common genital cancers in men and women such as cancers of the anus, vagina, penis, and vulva. HPV infection also causes genital warts in menand women.
The most common HPV types that infect the genital area are HPV types 6, 11, 16, and 18. Among these, HPV types 6 and 11 are most commonly associated with benign lesions, such as genital warts and mild precancerous changes of the cervix. In contrast, HPV types 16 and 18 are the types found in the majority of cancers as well as in severe precancerous changes of the cervix. The vaccine, called Gardasil, targets these four common HPV types.

Although cervical cancers start from cells with pre-cancerous changes (pre-cancers), only some of the women with pre-cancers of the cervix will develop cancer. The change from cervical pre-cancer to cervical cancer usually takes several years, but it can happen in less than a year. For most women, pre-cancerous cells will go away without any treatment. Still, in some women pre-cancers turn into true (invasive) cancers.


"A Must Have for Cervical Cancer Patients "

Cervical Cancer Statistics

CERVICAL CANCER  How Many Women Affected Today

Cervical cancer used to be the leading cause of cancer death for women in the United States. However, in the past 40 years, the number of cases of cervical cancer and the number of deaths from cervical cancer have decreased significantly. This decline largely is the result of many women getting regular Pap tests, which can find cervical precancer before it turns into cancer.1 For more information, visit HPV-Associated Cervical Cancer Rates by Race and Ethnicity.
In 2008 (the most recent year numbers are available)—
  • 12,410 women in the United States were diagnosed with cervical cancer.*2
  • 4,008 women in the United States died from cervical cancer.*2
*Incidence and death counts cover approximately 100% of the U.S. population.
Cervical cancer incidence is related to age but it is unusual as it does not follow the same pattern of increasing incidence with age seen for most cancers  There are two peaks in the age-specific incidence rates: the first in women aged 30-34 (at 21.2 per 100,000 women) and the second in women aged 80-84 (at 14 per 100,000 women). The earlier peak is related to many women becoming sexually active in their late teens/early 20s, giving rise to the increase of the Human Papilloma Virus (HPV - a precursor to cervical cancer development). The second peak is due to increasing cancer incidence with age. In the UK between 2007 and 2009, an average of 21% of new cervical cancer cases were in people aged 65 years and over.
Over three-quarters (76%) of cervical cancer cases occur in 25-64 year olds. Women in England and Northern Ireland are currently offered cervical cancer screening at three to five year intervals between ages 25 and 64. For women in Wales, screening is offered between the ages of 20 and 64 every three years. In Scotland, women are offered screening every three years between the ages of 20 and 60

Worldwide, cervical cancer is the third most common cancer in women and the seventh most common overall (in both sexes combined). It is estimated to be responsible for 530,000 new cases of cancer in 2008 (nearly one in ten (9%) of all cancers diagnosed in women). Cervical cancer incidence rates are lowest in Western Asia and highest in Eastern Africa, with a seven-fold variation in World AS incidence rates between the regions of the world.
For More Details Please check this Site:

Tuesday, July 17

OVARIAN CANCER  Scary Disease Of Women
(See Video Below)
Ovarian cancer is the ninth most common cancer among women, excluding non-melanoma skin cancers. It ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Ovarian cancer accounts for about 3% of all cancers in women. A woman's risk of getting ovarian cancer during her lifetime is about 1 in 71. Her lifetime chance of dying from ovarian cancer is about 1 in 95.

This year, an estimated 22,280 women in the United States will be diagnosed with ovarian cancer. It is estimated that 15,500 deaths from this disease will occur this year. Ovarian cancer accounts for nearly 3% of all cancers among women. It is the ninth most common cancer and fifth most common cause of cancer-related death in women.

Ovarian cancer is most common in women who have had the menopause (usually over the age of 45), but it can affect women of any age.
As the symptoms of ovarian cancer can be similar to those of other conditions, it can be difficult to recognise. However, there are early symptoms to look out for, such as pain in the pelvis and lower stomach, persistent bloating and difficulty eating.

There are several types of ovarian cancer. 

  • epithelial ovarian cancer, which affects the surface layers of the ovary; it is by far the most common type 
  • germ cell tumours, which originate in the cells that make the eggs
  • stromal tumours, which develops within the cells that hold the ovaries together
Epithelial ovarian cancer is by far the most common type of ovarian cancer. This information concentrates on epithelial ovarian cancer.

The exact cause of ovarian cancer is unknown, although a number of possible factors are thought to be involved, such as the number of eggs the ovaries release, and whether someone in your family has had ovarian cancer in the past. However, only one in 10 cases of ovarian cancer has a genetic link.
These are the stages of ovarian cancer:
  • Stage I: Cancer cells are found in one or both ovaries. Cancer cells may be found on the surface of the ovaries or in fluid collected from the abdomen.
  • Stage II: Cancer cells have spread from one or both ovaries to other tissues in the pelvis. Cancer cells are found on the fallopian tubes, the uterus, or other tissues in the pelvis. Cancer cells may be found in fluid collected from the abdomen.
  • Stage III: Cancer cells have spread to tissues outside the pelvis or to the regional lymph nodes. Cancer cells may be found on the outside of the liver.
  • Stage IV: Cancer cells have spread to tissues outside the abdomen and pelvis. Cancer cells may be found inside the liver, in the lungs, or in other organs.
There are no standard recommendations for screening for ovarian cancer. Screening women with pelvic ultrasound or blood tests, such as the Ca-125 has not been found to be effective and is not recommended.
BRCA testing may be done in women at high risk for ovarian cancer.
Removal of the ovaries and tubes in women who have a mutation in the BRCA1 and BRCA2 genes may reduce the risk of developing ovarian cancer, although ovarian cancer may still develop in other areas of the pelvis.


" A Must Have for Ovarian Cancer Patients! "